Compare UVSP & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVSP | CSTL |
|---|---|---|
| Founded | 1876 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 983.8M | 806.3M |
| IPO Year | 1994 | 2019 |
| Metric | UVSP | CSTL |
|---|---|---|
| Price | $37.83 | $25.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $36.67 | ★ $45.50 |
| AVG Volume (30 Days) | 185.3K | ★ 257.1K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | ★ 21.32 | N/A |
| EPS | ★ 3.13 | N/A |
| Revenue | $328,056,000.00 | ★ $344,229,000.00 |
| Revenue This Year | $11.65 | $2.42 |
| Revenue Next Year | $4.77 | $12.69 |
| P/E Ratio | $12.00 | ★ N/A |
| Revenue Growth | ★ 9.64 | 3.66 |
| 52 Week Low | $27.91 | $14.59 |
| 52 Week High | $38.71 | $44.28 |
| Indicator | UVSP | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 68.07 | 47.98 |
| Support Level | $32.00 | $21.77 |
| Resistance Level | N/A | $26.44 |
| Average True Range (ATR) | 1.03 | 1.16 |
| MACD | 0.04 | 0.24 |
| Stochastic Oscillator | 78.07 | 63.39 |
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.